...
首页> 外文期刊>Cancer Cell >Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma.
【24h】

Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma.

机译:鉴定人肝和肝细胞癌中的miRNomes揭示了miR-199a / b-3p作为肝细胞癌的治疗靶标。

获取原文
获取原文并翻译 | 示例
           

摘要

The full scale of human miRNome in specific cell or tissue, especially in cancers, remains to be determined. An in-depth analysis of miRNomes in human normal liver, hepatitis liver, and hepatocellular carcinoma (HCC) was carried out in this study. We found nine miRNAs accounted for approximately 88.2% of the miRNome in human liver. The third most highly expressed miR-199a/b-3p is consistently decreased in HCC, and its decrement significantly correlates with poor survival of HCC patients. Moreover, miR-199a/b-3p can target tumor-promoting PAK4 to suppress HCC growth through inhibiting PAK4/Raf/MEK/ERK pathway both in vitro and in vivo. Our study provides miRNomes of human liver and HCC and contributes to better understanding of the important deregulated miRNAs in HCC and liver diseases.
机译:在特定细胞或组织中,尤其是在癌症中,人miRNome的完整规模仍有待确定。本研究对人类正常肝脏,肝炎肝和肝细胞癌(HCC)中的miRNomes进行了深入分析。我们发现九种miRNA约占人类肝脏miRNome的88.2%。在肝癌中,表达水平第三高的miR-199a / b-3p持续下降,其减少与肝癌患者的不良生存率显着相关。而且,miR-199a / b-3p可以在体内外通过抑制PAK4 / Raf / MEK / ERK途径,靶向促肿瘤的PAK4抑制HCC的生长。我们的研究提供了人类肝脏和HCC的miRNome,并有助于更好地了解HCC和肝病中重要的失控miRNA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号